Lifting the fog over ITP

References

• Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, Chong BH, Cines DB, Gernsheimer TB, Godeau B, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010;115:168–186. doi:10.1182/blood-2009-06-225565.
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009;113:2386–2393. doi:10.1182/blood-2008-07-162503.
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood 2009;113:6511–6521. doi:10.1182/blood-2009-01-129155.
   PubMed Web of Science ®Google Scholar
• Arnold DM. Platelet count or bleeding as the outcome in ITP trials? Am J Hematol 2012;87:945–946. doi:10.1002/ajh.23299.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wong RSM, Soo YOY, Chui CH, Lau FY, Chan NPH, Wong WS, Cheng G. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003;349:831–836. doi:10.1056/NEJMoa030254.
   PubMed Web of Science ®Google Scholar
• Neunert CE, Buchanan GR, Imbach P, Bolton-Maggs PHB, Bennett CM, Neufeld EJ, Vesely SK, Adix L, Blanchette VS, Kühne T. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 2008;112:4003–4008. doi:10.1182/blood-2008-03-138487.
   PubMed Web of Science ®Google Scholar
• Provan D, Newland AC. Current management of primary immune thrombocytopenia. Adv Ther 2015;32:875–887. doi:10.1007/s12325-015-0251-z.
   PubMed Web of Science ®Google Scholar
• Neunert CE. Individualized treatment for immune thrombocytopenia: predicting bleeding risk. Semin Hematol 2013;50:S55–S57. doi:10.1053/j.seminhematol.2013.03.009.
   PubMedGoogle Scholar
• Patel VL, Mahevas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, Kanter J, Neufeld E, Taube T, Ramenghi U, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood 2012;119:5989–5995. doi:10.1182/blood-2011-11-393975.
   PubMed Web of Science ®Google Scholar
• Wei Y, Ji XB, Wang YW, Wang JX, Yang EQ, Wang ZC, Sang YQ, Bi ZM, Ren CA, Zhou F, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. Blood 2016;127:296–302. quiz 370. doi:10.1182/blood-2015-07-659656.
   PubMed Web of Science ®Google Scholar
• Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Blood Adv 2017;1:2295–2301. doi:10.1182/bloodadvances.2017009860.
   PubMed Web of Science ®Google Scholar
• Bussel JB, Lee CS, Seery C, Imahiyerobo AA, Thompson MV, Catellier D, Turenne IG, Patel VL, Basciano PA, Elstrom RL, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica 2014;99:1264–1271. doi:10.3324/haematol.2013.103291.
   PubMed Web of Science ®Google Scholar
• Choi PY, Roncolato F, Badoux X, Ramanathan S, Ho SJ, Chong BH. A novel triple therapy for ITP using high dose dexamethasone, low dose rituximab and cyclosporine (TT4). Blood 2015;126:500–503. doi:10.1182/blood-2015-03-631937.
   PubMed Web of Science ®Google Scholar
• Sun L, Liu X, Zhou H, Zhao H, Yuan C, Li D, Wang Z, Hou Y, Peng J, Hou M. High-Dose Dexamethasone (HD-DXM) plus oseltamivir versus high-dose dexamethasone for treatment of adult primary immune thrombocytopenia: interim analysis of a prospective, multicenter, randomized, controlled trial. Blood 2019;134:900–900. doi:10.1182/blood-2019-121825.
   PubMedGoogle Scholar
• Huang Q-S, Liu Y, Wang J-B, Peng J, Hou M, Liu H, Wang J-W, Xu L-P, Liu K, Huang X-J, et al. Combination of ATRA and high-dose dexamethasone as first-line treatment in adult immune thrombocytopenia:a randomized, phase 2, open-label trial. Blood 2019;134:899–899. doi:10.1182/blood-2019-125242.
   Google Scholar
• Broome CM, Röth A, Kuter DJ, Scully M, Smith R, Wang J, Reuter C, Hobbs W. Inhibition of the classical pathway of complement with sutimlimab in chronic immune thrombocytopenic purpura patients without adequate response to two or more prior therapies. Blood 2019;134:898–898. doi:10.1182/blood-2019-122210.
   Google Scholar
• Robak T, Kaźmierczak M, Jarque I, Musteata V, Trelinski J, Cooper N, Kiessling P, Massow U, Woltering F, Snipes R, et al. Rozanolixizumab, an anti-FcRn antibody: final results from a phase II, multiple-dose study in patients with primary immune thrombocytopenia. Blood 2019;134:897–897. doi:10.1182/blood-2019-129839.
   Google Scholar
• Newland AC, Sánchez-González B, Rejtő L, Egyed M, Romanyuk N, Godar M, Verschueren K, Gandini D, Ulrichts P, Beauchamp J, et al. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Blood 2019;134:895–895. doi:10.1182/blood-2019-128022.
   Google Scholar
• Kuter DJ, Boccia RV, Lee E-J, Efraim M, Tzvetkov N, Mayer J, Trněný M, Kostal M, Hajek R, McDonald V, et al. Phase I/II, open-label, adaptive study of oral bruton tyrosine kinase inhibitor PRN1008 in patients with relapsed/refractory primary or secondary immune thrombocytopenia. Blood 2019;134:87–87. doi:10.1182/blood-2019-122336.
   Google Scholar